StockIQ.techBayer Aktiengesellschaft (BAYN.DE) Stock Analysis
Free AI-powered analysis and research for Bayer Aktiengesellschaft stock
Sector: Healthcare
BAYN.DE snapshot
Data as of 3 Nov 2026 close. Updated daily.
Bayer Aktiengesellschaft scores 49/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 92% of its 52-week range, up 95.8% over the past year. Latest reported figures show a profit margin of -3.8%, return on equity of -5.7% and revenue growth of +1.2%.
What is driving the score
- Mixed Trend: +0
- MACD Bullish: +8
- Unprofitable (-3.8%): -15
- Weak Liquidity (1.04 Current Ratio): -5
- Negative ROE (-5.7%): -10
- Strong Long-term Uptrend: +8
- Strong Rise (+95.8% over 1 year): +10
- High Volume (3.1x): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BAYN.DE report
Bayer Aktiengesellschaft (BAYN.DE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BAYN.DE Now →📰 Latest Update
Bayer Raises Profit Outlook Helped by Strong Demand for Drugs
Tue, November 3, 2026 at 6:44 AM UTC 4 min read
Bayer AG (BAYN.DE) has raised its annual profit outlook due to a strong performance in its pharmaceutical unit, driven by high demand for newer drugs like Nubeqa and Kerendia. The company now expects adjusted earnings before interest, tax, depreciation, and amortization to reach between €9.8 billion and €10.3 billion, up from a previous forecast of €9.6 billion to €10.1 billion. Bayer also exceeded analyst expectations for its third-quarter earnings.